Emerald Advisers LLC Sells 1,061 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

Emerald Advisers LLC trimmed its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 55.5% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 852 shares of the biotechnology company's stock after selling 1,061 shares during the period. Emerald Advisers LLC's holdings in United Therapeutics were worth $263,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Dunhill Financial LLC lifted its stake in shares of United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 50 shares during the period. Sound Income Strategies LLC acquired a new stake in United Therapeutics during the 1st quarter worth $49,000. State of Wyoming acquired a new stake in United Therapeutics during the 4th quarter worth $62,000. Millstone Evans Group LLC acquired a new stake in United Therapeutics during the 4th quarter worth $67,000. Finally, Curat Global LLC acquired a new stake in United Therapeutics during the 1st quarter worth $63,000. 94.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the completion of the transaction, the executive vice president owned 36,781 shares in the company, valued at approximately $10,297,208.76. This trade represents a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Richard Giltner sold 3,036 shares of United Therapeutics stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total value of $879,225.60. Following the transaction, the director owned 19,384 shares of the company's stock, valued at $5,613,606.40. The trade was a 13.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 84,681 shares of company stock worth $25,261,669 over the last three months. Company insiders own 10.30% of the company's stock.

United Therapeutics Trading Up 1.8%

Shares of NASDAQ UTHR traded up $5.24 during mid-day trading on Wednesday, hitting $298.48. The company had a trading volume of 152,236 shares, compared to its average volume of 442,699. The company has a market capitalization of $13.46 billion, a PE ratio of 11.91, a price-to-earnings-growth ratio of 6.51 and a beta of 0.53. The firm has a 50-day simple moving average of $300.99 and a two-hundred day simple moving average of $319.11. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating the consensus estimate of $6.29 by $0.34. The company had revenue of $794.40 million during the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. United Therapeutics's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter last year, the company earned $6.17 EPS. Sell-side analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on UTHR shares. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Bank of America dropped their price objective on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research note on Wednesday, June 11th. HC Wainwright reaffirmed a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a research note on Monday, May 5th. Wall Street Zen downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Finally, UBS Group cut their price target on United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a report on Monday, June 30th. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $383.08.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.